Kim et al. developed high-density lipoprotein-mimetic nanoparticles (eHNPs) incorporated with apolipoprotein A1 (to enhance the BBB crossing) and anti-CD15 (a murine SHH MB cancer stem-like cell target) to achieve dual targeting and a SHH inhibitor (Sonidegib (LDE225)) to affect CSCs. Here, APOA1 is linked to cancer.